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Sevrages opiacés de types ultra-courts, effectués sous sédation profonde après 
prémédication à la buprénorphine : résultats à longs termes. 
Contexte : les méthodes de sevrage dit ultra-court pratiquées sous sédation intraveineuse 
font actuellement l'objet de controverses en raison du manque de données concernant leur 
suivi à long terme d'une part et leur sécurité d'autre part. La prémédication avec de la 
buprénorphine est préconisée puisqu'elle diminue les vomissements survenant au cours de 
la procédure de type ultra-courte. Enfin, les résultats des recherches antérieures ne se 
rapportent pas à des populations de patients socialement défavorisés. 
Méthode : Seize patients dépendants des opiacés ont bénéficié d'un sevrage ultra-court puis 
ont été prospectivement évalués sur une période d'au moins 30 mois. Les données de cette 
procédure ont été comparées avec celles de notre étude précédentes effectuée sans 
préparation avec de la buprénorphine. Des médecins généralistes ont entièrement géré la 
phase de pré et post-procédure (prémédication à la buprénorphine, suivi après sevrage). 
Résultats : durant la procédure, seul un épisode de vomissement est survenu au lieu de 13 
sur 20 dans notre précédente étude. Post-procédure, seuls deux patients se sont plaints 
durant 24 à 48 heures d'un état de manque modéré sous forme de nausées persistantes, 
crampes abdominales et vomissements au lieu de la plupart des patients dans notre étude 
précédente. Après une période d'au minimum 30 mois (36.0 ± 6.38), les 16 patients sont 
toujours en vie et régulièrement suivis par leur médecin généraliste. Deux d'entre eux sont 
restés totalement abstinents après le sevrage et quatorze ont rechuté. Parmi ces quatorze 
patients, douze ont suivi, après la rechute, un traitement de substitution à la méthadone. 
Deux sont resté héroïne-dépendants. 
Conclusion : dans ce petit échantillon de patients, les données ont montré que la sécurité 
des sevrages de type ultra-court est significativement améliorée avec une prémédication à la 
buprénorphine. Aucun patient n'est décédé sur une période d'au moins 30 mois. De plus, la 
procédure a été effectuées avec des patients socialement défavorisés. Sur le long terme 
deux d'entre eux sont restés abstinents tandis que la majorité a opté pour un traitement de 
substitution après la rechute ce qui tend à montrer que le sevrage de type ultra-court peut 
s'inscrire comme l'une des étapes possibles dans une prise en charge à long terme. 
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Abstract 
Background: New methods of ultra-rapid opiate detoxification (URD) under intravenous sedation have been criticized because of 
limited data on safety and long-term follow-up. Premedication with buprenorphine has been advocated to improve safety by 
decreasing vomiting. Prior research has not explored URD in socially impaired patients. Methocl: Sixteen patients were detoxified 
with URD and prospectively evaluated over at least 30 months. Data of this procedure were compared with those of our previous 
study without buprenorphine preparation (Drug Alcohol Depend. 52(3) (1998) 243). The 16 patients were followed up by a general 
practitioner (GP) before and after URD. The GPs also supervised the 7-day course ofbuprenorphine treatment prescribed for the 16 
patients prior to URD. Results: During the procedure, only one episode ofvomiting occurred instead of 13 out of20 in our previous 
study. Post-procedure, only two patients experienced moderate withdrawal symptoms, such as persistent nausea, abdominal cramps 
and vomiting lasting from 24 to 48 h, in comparison with most patients in the previous study without buprenorphine. After a period 
of at least 30 months (36.0 ± 6.38), the 16 patients were still alive and were regularly monitored by their GP. Only two of the 16 never 
relapsed after URD and reported total opiate abstinence. Fourteen patients relapsed; 12 of these were prescribed a licensed 
methadone substitution program and two were still using heroin. Conclusion: In this small sample, the data indicated that URD with 
buprenorphine preparation was safe and that it markedly decreased post-procedure morbidity. No patient died over a minimum 30-
month follow-up period. Furthermore, the procedure was employed with socially impaired patients. In the long term, a few patients 
were still free of opiates, while the majority opted for a methadone maintenance program, showing that URD can serve as one 
possible step in a long-term treatment program. 
© 2002 Elsevier Science lreland Ltd. All rights reserved. 
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1. Introduction 
Ultra-rapid opiate detoxification (URD), also known 
as anesthesia-assisted or 1-day opiate detoxification, is a 
procedure for detoxifying opioid-dependent patients 
with opiate antagonists, such as naloxone/naltrexone, 
administered either under general anesthesia or under 
deep sedation. 
* Corresponding author. Present address: Division d'Abus de 
Substances, Centre Saint-Martin, Rue Saint-Martin 7, 1003 
Lausanne, Switzerland. Tel.: +41-21-316-1601; fax: +41-21-316-1636. 
E-mail address: jacqnes.besson@inst.hospvd.ch (J. Besson). 
The method was first developed by Loimer et al. 
(1989) with patients under anesthesia and intubation 
and was based on earlier rapid detoxification methods 
published by the Yale group in the early 1980s (Riordan 
and !Geber, 1980; Vining et al., 1988). Numerous groups 
then worked on improving the technique. Loimer et al. 
(1991) refined the procedure with patients under deep 
intravenous midazolam sedation and proposed that 
patients should transfer to oral naltrexone 2-3 h post-
procedure. Loperamide (Legarda and Gossop, 1994) or 
octreotide were added to prevent diarrhoea and ondan-
setron was prescribed against nausea (Loimer et al., 
1993). Recently, the International Group for Rapid 
Opiate Detoxification (IGROD) reported on several 
03765-8716/02/$ - see front malter© 2002 Elsevier Science Ireland Ltd. All rights reserved. 
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developments, including the introduction of buprenor-
phine premedication prior to URD (Brewer, 1997). 
This latter approach, first suggested by Stine and 
Kosten (1992), is based on the opiate agonist/antagonist 
properties of buprenorphine, which bas less potential for 
drug dependence than a pure agonist. Its use as a 
substitution treatment at least 1 week before detoxifica-
tion decreases the intensity of the withdrawal syndrome. 
Furthermore, this period of preparation is a good way 
to evaluate patient motivation. 
However, much controversy currently surrounds 
URD because of its associated risks of mortality and 
morbidity (Dyer, 1998). Deep sedation without intuba-
tion involves the dangers of branchial aspiration, 
nosocomial aspiration, pneumonia and the need for 
tracheal intubation in 1.3-2.6% of patients (Seoane et 
al., 1997). Even with intubation, Pfab et al. (1999) 
reported the onset of episodes of pulmonary and renal 
failure and thyroid hormone suppression during the 
procedure. 
Nevertheless, limited data is available regarding 
patient outcome after URD. A literature review from 
1989 to 1998 (O'Connor and Kosten, 1998) revealed 
studies with follow-up periods ranging from 1 week to 1 
month. Most of these studies evaluated withdrawal 
scales rather than patient outcome. Recent reports 
indicated relapse rates from 36 to 80% after 6-12 
months (Cucchia et al., 1998; Rabinowitz et al., 1998; 
Albanese et al., 2000). 
Considering the lack of long-term outcome data after 
URD, this paper addresses the question by evaluating 
16 opioid-dependent socially impaired patients at least 
30 months after URD. 
2. Method 
2.1. General design 
This study evaluated the follow-up of 16 opioid-
dependent patients detoxed with a URD procedure after 
a 7-day course of buprenorphine. The 16 patients left 
hospital 24 h after URD to attend a residential or 
outpatient treatment program. Their GPs usually as-
sumed responsibility for follow-up with a substance 
abuse treatment program (shared care). At least 30 
months (36.0 ± 6.38) after the initial evaluation, the 16 
patients (100% follow-up) were evaluated by a research 
assistant and asked to complete a questionnaire. 
The study was approved by the Ethics Committee of 
the Department of Psychiatry of the University of 
Lausanne. 
Descriptive statistics were used to present the results. 
In the data analysis, the Student's t-test was used for the 
dimensional variable, while the x2-test was employed for 
data expressed as ratios. Correlations were incorporated 
using the Pearson's coefficient. Statistical analyses were 
performed with SPSS for Windows (9.0). Continuous 
results are reported as means ± S.D. 
2.2. Population studied 
Sixteen patients were included; 12 men and four 
women with a mean age of 29 ± 5.98 years. Only five 
of the 16 patients were currently employed at the time of 
the URD. Ali had been opiate-dependent (DSM-IV) for 
at least 3 years, mean 8.1±5.87 years (from three to 20). 
At the time of the URD evaluation, nine patients were 
receiving methadone maintenance therapy (mean dose 
53.0±33.44 mg). The other seven patients were heroin-
dependent with daily drug use from two to five times a 
day (intravenously in five of the seven) and with a total 
estimated daily dose of 1-3 g. Three patients also 
admitted to occasional benzodiazepine use and one 
was dependent on cocaine. Three of the nine patients 
on methadone maintenance therapy used heroin ap-
proximately every other month. 
The 16 URD candidates were personally interviewed 
by a senior psychiatrist (G.B.) who assessed the diag-
nosis of opiate dependence according to DSM-IV. 
Unmotivated patients or those with severe psychiatrie 
disorders, such as schizophrenia or bipolar disease, were 
excluded. The indications for URD were: detoxification 
before admission to a therapeutic community (n = 4), a 
new occupation or training (11 = 10) or a long journey 
abroad (11 = 2). All had previously experienced out-
patient detoxification and had left hospital with a 
naltrexone treatment (50 mg per day). 
2.3. Ultra-rapid opiate detoxificatio11 procedure 
One week before URD, all the patients switched from 
heroin or methadone to buprenorphine at a starting 
dose of 3 mg when withdrawal symptoms appeared. 
Accordingly, patients on methadone waited 40-60 h 
before starting buprenorphine. Those with methadone 
doses exceeding 30 mg per day received clonidine (0.075 
mg four to six times a day) during this period of 40-60 
h. Buprenorphine doses were added to achieve complete 
resolution of withdrawal symptoms. The patients deter-
mined the minimum dosage needed to make them feel 
comfortable. This dose generally decreased from 7.4 ± 
4.61 mg on the first day to 4.3±2.66 mg on the day 
preceding URD. Each patient underwent a physical 
examination, an electrocardiogram and blood tests, 
including blood count, electrolytes, urea, creatinine 
and transaminases. 
On the day of URD, patients were admitted to our 
hospital at 07:30 h with an empty stomach. The 
procedure started with simultaneous oral administration 
of clonidine 0.300 mg, midazolam 60-135 mg (accord-
ing to the subject's experience with benzodiazepines), 
C. Bochud Tol'llay et al. I Drng li/Id Alcohol Depe11dence 69 (2003) 283-288 285 
ondansetron 16 mg and loperamide 16 mg. When the 
first signs of sleepiness appeared, patients received 50 
, mg of naltrexone. Thirty to 60 min la ter, they entered 
the most acute phase of the withdrawal for 2-4 h. 
During this and the initiation phase, a nurse and a 
physician were responsible for the monitoring (perma-
nent control of cardiac activity and oxygen saturation as 
well as blood pressure every 30 min). Oxygen therapy by 
mask, broncho-aspiration and tracheo-intubation mate-
rial was available in the room and the physician on duty 
had been trained to use them. 
Patients remained under constant nursing attention 
until they awoke spontaneously and remained awake for 
sufficient time (sometime between 6 and 10 h after the 
initiation). When they showed excessive global or 
specific withdrawal symptoms, additional medication 
was administered by mouth or by intramuscular injec-
tion i.n case of vomiting or abdominal cramps. During 
the first 24 h, the mean (±S.D.) medication was as 
follows: clonidine O. 51 ± 0.16 mg, benzodiazepines 
127.5 ±~3.47 mg, ondansetron 19.3 ±3.66 mg and 
loperam1de 20.3 ± 5. 74 mg. Patients left hospital after 
24 h under naltrexone (50 mg per day) with a 2-3 day 
supply of clonidine and benzodiazepine. The GPs, in 
collaboration with the substance abuse therapeutic 
netw~rk, were responsible for the buprenorphine pre-
parat10n and post-treatment phase. 
2. 4. Follow-up 
Patients were located with the help of their GP and 
we~·e mailed a follow-up questionnaire. The question-
naire evaluat.ed aspects of the post-treatment phase, 
such as durat10n of abstinence, naltrexone intake, use of 
unprescribed medication, use ofillegal drugs, number of 
new detoxification attempts, introduction of a new 
~nethadone maintenance therapy, physical or mental 
1llnesses after URD. Visual analogue scales ranging 
from zero to ten points were used to determine the 
patients' satisfaction regarding URD. The correspond-
mg statements were: 'I never underwent such a hardi 
easy detoxification'; 'I would choose another/the same 
meth~~ if. I, n~eded. to undergo another in-patient 
detox1flcat10n ; I thmk that URD was of no use/ 
extremely useful in my progress towards abstinence'. 
3. Results 
Th~ .16 .patients (100%) successfully completed the 
detox1flcat10n process and were discharged on naltrex-
one .. ~omplications were limited to one episode of 
vom1t111g during the procedure instead of 13 out of 20 
found i~ our previous study withôut buprenorphine 
preparation (Cucchia et al., 1998) (P < 0.001). Thus, in 
our present study, the mean (±S.D.) dose of ondanse-
tron during the first 24 h was 19.3±3.66 vs. 28±12 mg 
(P < 0.05) in the previous study. No tracheal intubation 
was required. Only two patients experienced moderate 
withdrawal symptoms, such as persistent nausea ab-
dominal cramps and vomiting lasting from 24 to '48 h 
post~pro~edure, whereas most patients had complained 
of digestive symptoms in our previous study. However 
ail patients in both studies complained of psychi~ 
symptoms, insomnia and anxiety in the week following 
the procedure. 
The 16 patients were located at least 30 months after 
URD and .were interviewed (100% follow-up rate). 
T':elve patients (75%) returned completed question-
naires and four (25%) answered over the telephone. Of 
the 16 patients, four (25%) had been abstinent after 1 
year and two (12.5%) remained abstinent after at least 
30 months (see Fig. 1 ). Finally, of the 11 patients who 
had b.een unemployed at the time of the study, six were 
back 111 work at the time of the interview. 
The degree of satisfaction was closely related to the 
duration of abstinence: 'I would choose another/the 
same .n:eth.od ,if I needed to undergo another in-patient 
detox1flcat10n, r = 0.55 (P < 0.01); 'I never underwent 
such a hard/easy detoxification', r = -0.49; 'I think that 
URD was of no use/extremely useful in my progress 
towards abstinence', r = -0.56. The global satisfaction 
level (based on the mean scores for the three questions 
for each patient) was 6.0 ± 3.91 (P < 0.0001) and showed 
that the global satisfaction level was significantly higher 
among those patients (11 = 10) who remained abstinent 
for more than 1 month Fig. 2. 
At the time of the study, two (12.5%) out of the 16 
patients reported total abstinence after URD and never 
relapsed. Both were under methadone maintenance 
befor~ URD. Ail other patients (n = 14, 87.5%) relapsed 
on opiates after URD. Twelve were prescribed a licensed 
methadone substitution program. At the time of the 
study, two of the 12 had completed their methadone 
tre~tment and had been abstinent for more than 1 year, 
wh!le ten were still following methadone treatment 
Finally, two (12.5%) of the 14 relapsers attempted 
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Fig. 1. Thirty-month survival (abstinence) profile after URD (11 = 16). 
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Fig. 2. Degree of satisfaction reported during the period of abstinence 
after URD. 
another detoxification (not URD). They were still 
dependent on heroin at the time of the study, but still 
receiving treatment from their GP and connected to 
social services. Among the 14 relapsers, seven were 
heroin dependent and seven methadone dependent. 
Relapsers who were on methadone before URD re-
turned to methadone, while five heroin dependent 
patients switched to methadone substitution treatment. 
Fig. 3 categorizes the different forms of outcome for the 
16 patients, 30 months after URD. 
Among the 14 relapses, seven occurred during the first 
month after URD, five between the second and twelfth 
month and two between the thirteenth and eighteenth 
month. The seven earliest relapsers explained that they 
had suffered severe residual withdrawal syndrome and 
had stayed in close contact with drug dealers, while the 
others mentioned emotional problems and a general 
lack of satisfaction with their lives. 
Fig. 4 evaluated the relationship between the duration 
of abstinence (month) and the duration of naltrexone 
use. None of the sevèn first-month relapsers were on 
naltrexone, while those on naltrexone for more than 30 
days remained abstinent for at least 6 months. Two out 
of the three patients who had taken naltrexone for just 1 
day and remained abstinent for 6 months, entered a 
therapeutic community directly after URD. The third 
immediately left the country in a very isolated context. 
Naltrexone intake was similar between the heroin 
dependent patients and those under methadone main-
tenance (mean of 17 vs. 19 days, respectively, P = 0.9). 
4. Discussion 
AU patients (100%) were located and interviewed after 
almost 3 years, despite their initial socially impaired 
situation. AU were alive and still being regularly 
monitored by their GPs. At the time of the study, 75% 
of the patients had followed, or were still following, a 
methadone substitution program. This means that the 
30-month relapse rate was high (87.5%). Nevertheless, 
patients globally reported a high degree of satisfaction 
(mean 6.0±3.91) for URD. This paradoxical high 
degree of satisfaction was probably linked with the 
integration of the patients in a therapeutic addiction 
network after the URD. This shared-care program, 
involving close collaboration between GPs, specialists, 
pharmacists and social services, offered the patients the 
possibility of avoiding the social, legal and infections 
complications of opiate addiction. The prescription of 
methadone substitution treatment under the supervision 
of GPs probably decreased the stigmatization of the 
patients and may have helped attract them to the 
therapeutic network and to keep them within it. Con-
sequently, for most of the patients unemployment 
decreased and parallel illegal drug consumption disap-
peared. 
To our knowledge, this study involves the longest 
follow-up of patients after URD. In contrast with 
previously published data, this study did not include 
high-functioning patients with a good prognosis, since 
the main acceptance criterion for URD was simply the 
motivation for detoxification. Most of the patients were 
unemployed and none had to pay for their treatment. In 
such conditions and by way of comparison, our relapse 
rate at 6 months (56.25%) was similar to that observed 
after classical in-patient detoxification programs (Gos-
sop et al., 1989; Broers et al., 2000). Our results also 
matched those of Albanese et al. (2000), who obtained a 
45% relapse rate with a comparable procedure on a 
sample of 123 patients. At 6 months, we found better 
results than those of Cucchia et al. (1998), who reported 
an 80% relapse rate with the same URD procedure but 
without buprenorphine preparation. The lower level of 
sicle effects provided by the buprenorphine preparation 
may have contributed to the difference (see below). At 1 
year however, our relapse rate was 75% compared with 
43% observed by Rabinowitz et al. (1998). Here, the 
main difference seems to be in the patient compliance 
for naltrexone treatment after URD. Rabinowitz et al. 
(1997) reported that the non-relapsed patients com-
pleted at least 5 months of naltrexone treatment. In our 
study, only four patients (25%) took naltrexone for 
more than 30 days, but all remained abstinent for more 
than 6 months. This confirms the results of Rabinowitz 
et al. (1997) and proves that more prolonged use of 
naltrexone is associated with less chance of relapse. 
The major controversy about URD concerns the 
associated risks of mortality and morbidity. Our experi-
ence shows that, with the deep sedation technique, 
buprenorphine preparation can improve safety since it 
significantly decreases the sicle effects observed during 
URD. Only one patient experienced vomiting during the 
procedure with buprenorphine preparation, compared 
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had required the use of tracheal intubation a risk of 
bronchial.aspi.rat~on does exist and explains ~hy general 
anaesthesia with mtubation may appear to be the safest 
method. Nevertheless, the mortality associated with 
~naesthesia itself remains between one in 1185 and one 
111 6789 for unselected patients (Brown, 1992). In such a 
context and since URD is an expensive procedure that 
ca~ cost as much as 2500-7500 US$ per patient 
(O Connor and Kosten, 1998), it appears that the 
me:hod should be evaluated individually for each 
pat1en: and .the costs carefully balanced against the 
potential savmgs afforded by this procedure. 
months of abstinence re-
ported for each patient 
~ig. 4. Months of abstinence in relation to the period of naltrexone 
mtake. 
Our study has several limitations. Firstly, we studied 
only a small number of patients and secondly, we did 
not use a control group. These results need to be 
replicated in a larger sample with a control group. 
Furthermore, GPs were contacted primarily to obtai 
~o the two-thirds of patients who experienced vomiting 
Ill the study reported by Cucchia et al. (1998). Never-
theless, even though none of these vomiting episodes tl . ' n ie patients addresses. Although we observed close 
similarities between their information and that of the 
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patients, we did not formally ask GPs for detailed 
follow-up information. Finally, future studies should 
evaluate more accurately those patient characteristics 
that could predict the success or failure of such 
procedures. 
In conclusion, this study showed that the URD 
procedure with deep sedation was easier and safer with 
buprenorphine preparation than without as in our 
previous study. After a period of 30 months, two of 
the 16 patients reported total opiate abstinence, 12 were 
on methadone maintenance and two were still opioid 
dependent. All the relapsers remained integrated within 
the therapeutic addiction network that they had joined 
after relapse. However, long term results were no better 
than those of classical detoxification. This suggests that 
in a context of socially impaired patients, URD may be 
an alternative option in detoxification even if long term 
abstinence is weak. 
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